68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET

Nuclear Medicine and Biology

Volumn 41, Issue 3, 2014, Pages 268-275

  Zhang, Jun ^a,b   Lu, Xiaoli ^a   Wan, Nan ^a   Hua, Zichun ^c   Wang, Zizheng ^a   Huang, Hongbo ^d   Yang, Min ^d   Wang, Feng ^a,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b TAIZHOU PEOPLE S HOSPITAL   (China)

^c NANJING UNIVERSITY   (China)

^d JIANGSU INSTITUTE OF NUCLEAR MEDICINE   (China)

Author keywords

68Ga labeling; APN; CD13; NGR peptide; Tumor angiogenesis

Indexed keywords

1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; DIAGNOSTIC AGENT; GALLIUM; MICROSOMAL AMINOPEPTIDASE; NGR PEPTIDE; OLIGOPEPTIDE; SINGLE HETEROCYCLIC RINGS; TETRAXETAN;

(68)GA LABELING; ANIMAL; APN; ARTICLE; CHEMISTRY; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; LUNG SMALL CELL CANCER; LUNG TUMOR; METABOLISM; METHODOLOGY; MOUSE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; TUMOR ANGIOGENESIS; TUMOR CELL LINE;

(68)GA LABELING; APN; CD13; NGR PEPTIDE; TUMOR ANGIOGENESIS;

ANIMALS; ANTIGENS, CD13; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; FEASIBILITY STUDIES; FEMALE; GALLIUM RADIOISOTOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; LUNG NEOPLASMS; MICE; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; SMALL CELL LUNG CARCINOMA;

EID: 84893904761     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.12.008     Document Type: Article

References (37)

1. Look A.T., Ashmun R.A., Shapiro L.H., Peiper S.C. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest 1989, 83:1299-1307.
2. Sjostrom H., Noren O., Olsen J. Structure and function of aminopeptidase N. Adv Exp Med Biol 2000, 477:25-34.
3. Tokuhara T., Hattori N., Ishida H., et al. Clinical significance of aminopeptidase N in non-small cell lung cancer. Clin Cancer Res 2006, 12:3971-3978.
4. Hashida H., Takabayashi A., Kanai M., et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 2002, 122:376-386.
5. Ishii K., Usui S., Sugimura Y., et al. Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer 2001, 92:49-54.
6. Wickström M., Larsson R., Nygren P., Gullbo J., Wickstrom M. Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci 2011, 102:501-508.
7. Saiki I., Fujii H., Yoneda J., et al. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer 1993, 54:137-143.
8. Fujii H., Nakajima M., Saiki I., Yoneda J., Azuma I., Tsuruo T. Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin Exp Metastasis 1995, 13:337-344.
9. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279:377-380.
10. Zou M., Zhang L., Xie Y., Xu W. NGR-based strategies for targeting delivery of chemotherapeutics to tumor vasculature. Anticancer Agents Med Chem 2012, 12:239-246.
11. Corti A., Curnis F. Tumor vasculature targeting through NGR peptide-based drug delivery systems. Curr Pharm Biotechnol 2011, 12:1128-1134.
12. Corti A., Pastorino F., Curnis F., Arap W., Ponzoni M., Pasqualini R. Targeted drug delivery and penetration into solid tumors. Med Res Rev 2012, 32:1078-1091.
13. Mammoliti S., Andretta V., Bennicelli E., et al. Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies. Ann Oncol 2011, 22:973-978.
14. Gregorc V., De Braud F.G., De Pas T.M., et al. Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors. Clin Cancer Res 2011, 17:1964-1972.
15. Gregorc V., Santoro A., Bennicelli E., et al. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. Br J Cancer 2009, 101:219-224.
16. Zucali P.A., Simonelli M., De Vincenzo F., et al. Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours. Br J Cancer 2013, 108:58-63.
17. von Wallbrunn A., Waldeck J., Höltke C., et al. In vivo optical imaging of CD13/APN-expression in tumor xenografts. J Biomed Opt 2008, 13:011007.
18. Buehler A., van Zandvoort M.A., Stelt B.J., et al. cNGR: a novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo. Arterioscler Thromb Vasc Biol 2006, 26:2681-2687.
19. Oostendorp M., Douma K., Wagenaar A., et al. Molecular magnetic resonance imaging of myocardial angiogenesis after acute myocardial infarction. Circulation 2010, 121:775-783.
20. Oostendorp M., Douma K., Hackeng T.M., et al. Quantitative molecular magnetic resonance imaging of tumor angiogenesis using cNGR-labeled paramagnetic quantum dots. Cancer Res 2008, 68:7676-7683.
21. Chen K., Ma W., Li G., et al. Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for microPET imaging of CD13 receptor expression. Mol Pharm 2013, 10:417-427.
22. Ma W., Kang F., Wang Z., et al. (99m)Tc-labeled monomeric and dimeric NGR peptides for SPECT imaging of CD13 receptor in tumor-bearing mice. Amino Acids 2013, 44:1337-1345.
23. Abdollahi A., Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010, 13:16-28.
24. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6:273-286.
25. Tateishi U., Oka T., Inoue T. Radiolabeled RGD peptides as integrin alpha(v)beta3-targeted PET tracers. Curr Med Chem 2012, 19:3301-3309.
26. Liu S. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 2009, 20:2199-2213.
27. Dijkgraaf I., Beer A.J., Wester H.J. Application of RGD-containing peptides as imaging probes for alphavbeta3 expression. Front Biosci 2009, 14:887-899.
28. Fukasawa K., Fujii H., Saitoh Y., et al. Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis. Cancer Lett 2006, 243:135-143.
29. Pasqualini R., Koivunen E., Kain R., et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000, 60:722-727.
30. Zhang Z., Harada H., Tanabe K., Hatta H., Hiraoka M., Nishimoto S. Aminopeptidase N/CD13 targeting fluorescent probes: synthesis and application to tumor cell imaging. Peptides 2005, 26:2182-2187.
31. Jiang W., Jin G., Ma D., et al. Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth. PLoS ONE 2012, 7:e37132.
32. Fani M., Andre J.P., Maecke H.R. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging 2008, 3:67-77.
33. Zhernosekov K.P., Filosofov D.V., Baum R.P., et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007, 48:1741-1748.
34. Breeman W.A.P., de Blois E., Sze Chan H., Konijnenberg M., Kwekkeboom D.J., Krenning E.P. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med 2011, 41:314-321.
35. Roesch F., Riss P.J. The renaissance of the (68)Ge/(68)Ga radionuclide generator initiates new developments in (68)Ga radiopharmaceutical chemistry. Curr Top Med Chem 2010, 10:1633-1668.
36. Virgolini I., Ambrosini V., Bomanji J.B., et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2010, 37:2004-2010.
37. Wu Y., Zhang X., Xiong Z., et al. microPET imaging of glioma integrin αvβ3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med 2005, 46:1707-1718.